Novartis signs over tuberculosis drug development, research program to TB Alliance

Novartis recently signed a global licensing agreement with Global Alliance for TB Drug Development (TB Alliance) for drug compounds to fight tuberculosis.

Under the terms of the agreement, the Novartis Institutes for Tropical Diseases, which discovered the compounds, will complete the transfer of its TB research and development to the stewardship of the TB Alliance.

TB Alliance will assume financial and operational responsibility for the continued research, development, approval and distribution of drug candidates in the portfolio.

"Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio," Mel Spigelman, the president and CEO of TB Alliance, said. "We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments."

Novartis said the alliance has the best resources to develop new drugs and treatments for tuberculosis, which kills more than 1.3 million people every year, according to the World Health Organization.

"TB is one of the scourges of the developing world and new medicines are desperately needed to combat its continued spread," Mark C. Fishman, the president of Novartis Institutes for BioMedical Research, said. "TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB."